Spruce Biosciences to Present at Upcoming Investor Conferences in March
Get Alerts SPRB Hot Sheet
Join SI Premium – FREE
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at two upcoming investor conferences taking place in March.
-
Leerink Global Healthcare Conference
Date and Time: March 9, 2026, at 11:20 a.m. ET
Format: Fireside chat and 1x1 meetings
Location: Miami, FL
-
The Citizens Life Sciences Conference
Date and Time: March 10, 2026, at 12:30 p.m. ET
Format: Fireside chat and 1x1 meetings
Location: Miami, FL
Interested parties can access the live webcasts for each conference on the events section of the Company’s website. An archived copy of the webcasts will be available for approximately 90 days.
About Spruce Biosciences
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need. To learn more, visit www.sprucebio.com and follow us on X, LinkedIn, Facebook and YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260302646693/en/
Media
Carolyn Hawley
Inizio Evoke Comms
[email protected]
[email protected]
Investors
Monique Kosse
Gilmartin Group
[email protected]
[email protected]
Source: Spruce Biosciences, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AEVEX Announces Multi-Year Marketing Partnership with the Washington Commanders
- AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
- Dynex Capital, Inc. Declares Common and Preferred Stock Dividends
Create E-mail Alert Related Categories
Business Wire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share